Therefore, analyses of a large unselected cohort of HCC patients generated by the real-world clinical practice would indicate that, among potential candidates to immunotherapy, no more than one-third of them are amenable to ICIs as a frontline approach, and this percentage further decreases considering combination therapies with anti-VEGF or TKI agents. This evidence concerns the gene VEGFA and hepatocellular carcinoma.